Estudo comparativo do uso da minociclina sistêmica versus corticoterapia sistêmica no tratamento de vitiligo em atividade

Miquelin, Gabriela Momente; Colferai, Mariana Morais Tavares; Steiner, Denise

doi:10.5935/scd1984-8773.20191121388

Cited by 1 publication

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The VIDA score was used to compare the two groups, and while both showed a statistically significant difference, the minocycline group showed a greater reduction, indicating that minocycline was more effective in controlling vitiligo activity. 22 There was no statistically significant difference between the average VIDA scores of patients who received minocycline 100 mg/day and those who received OMP 2.5 mg. However, patients who received OMP reported experiencing more side effects.…”

Section: Minocyclinementioning

confidence: 77%

“…9 All studies that have investigated the effect of minocycline on vitiligo lesions have reported a significant improvement in the lesions. 9,[22][23][24][25] However, in one study, no significant difference was observed between the group receiving minocycline and the group receiving OMP. 23 In another study, its effectiveness was reported to be less than phototherapy.…”

Section: Discussionmentioning

confidence: 93%

“…When comparing the effectiveness of minocycline (100 mg/day) and prednisolone (administered orally at a dosage of 0.3 mg/kg/day for 2 months, followed by 0.15 mg/kg/day in the third month) in controlling vitiligo activity, it was found that 100% of patients in the minocycline group showed control of the disease, compared to 60% in the prednisolone group. The VIDA score was used to compare the two groups, and while both showed a statistically significant difference, the minocycline group showed a greater reduction, indicating that minocycline was more effective in controlling vitiligo activity 22 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo

Jafarzadeh,

Pour Mohammad,

Khosravi

et al. 2024

Skin Research and Technology

View full text Add to dashboard Cite

Aims and objectivesThe purpose of this study is to investigate the effectiveness and safety of oral and injectable systemic treatments, such as methotrexate, azathioprine, cyclosporine, tofacitinib, baricitinib, corticosteroids, statins, zinc, apremilast, etc., for treating vitiligo lesions.MethodDatabases including PubMed, Scopus, and Web of Science were meticulously searched for studies spanning from 2010 to August 2023, focusing on systemic oral and injectable therapies for vitiligo, using comprehensive keywords and search syntaxes tailored to each database. Key data extracted included study design, treatment efficacy, patient outcomes, patient satisfaction, and safety profiles.ResultsIn a total of 42 included studies, oral mini‐pulse corticosteroid therapy (OMP) was the subject of six studies (14.2%). Minocycline was the focus of five studies (11.9%), while methotrexate, apremilast, and tofacitinib each were examined in four studies (9.5%). Antioxidants and Afamelanotide were the subjects of three studies each (7.1%). Cyclosporine, simvastatin, oral zinc, oral corticosteroids (excluding OMP) and injections, and baricitinib were each explored in two studies (4.8%). Azathioprine, mycophenolate mofetil, and Alefacept were the subjects of one study each (2.4%).ConclusionSystemic treatments for vitiligo have been successful in controlling lesions without notable side effects. OMP, Methotrexate, Azathioprine, Cyclosporine, Mycophenolate mofetil, Simvastatin, Apremilast, Minocycline, Afamelanotide, Tofacitinib, Baricitinib, Antioxidants, and oral/injectable corticosteroids are effective treatment methods. However, oral zinc and alefacept did not show effectiveness.

show abstract

Section: Minocyclinementioning

confidence: 77%